Nationwide telehealth◆Provider-guided care◆Transparent cash-pay pricing◆✓ FSA/HSA approved◆Tampa Bay in-home IV therapy◆Nationwide telehealth◆Provider-guided care◆Transparent cash-pay pricing◆✓ FSA/HSA approved◆Tampa Bay in-home IV therapy◆
Questions? Talk to our team813-575-0911Call us · 813-575-0911

BPC-157: What Human Studies Show and Where U.S. Policy Stands

What the human research on BPC-157 shows, what the FDA says about its safety, and what HHS's October 2026 draft enforcement-discretion policy does and does not allow.

Good to know: This is general education, not medical or legal advice. Prolong Health does not prescribe BPC-157.

What is BPC-157?

BPC-157 (short for "body protection compound 157") is a lab-made peptide, a short chain of 15 amino acids, based on a protein fragment found in human gastric juice. It became popular in fitness, sports, and wellness circles because of animal studies on tissue healing, including tendons, ligaments, muscle, and the gut. [4][5]

What does the research show?

This is where the hype and the evidence split apart. Almost all of the research on BPC-157 has been done in animals and cell cultures, not people.

  • A 2025 systematic review from orthopaedic surgeons found 36 eligible studies on BPC-157 for musculoskeletal healing: 35 were preclinical (animal or lab) studies and only 1 was a clinical study in humans. [4]
  • A 2026 systematic review of human evidence found three small studies with 30 people in total: knee-pain injections (16 people), bladder instillations for interstitial cystitis (12 people), and an IV safety pilot (2 people). [5]
  • Those studies reported symptom improvement in most participants and no treatment-related side effects, but the reviewers rated their quality as poor and the overall certainty of evidence as very low. [5]
  • The authors concluded that BPC-157 should not be used clinically outside of well-designed, regulated clinical trials. [5]

In plain terms: the animal results are interesting and explain the buzz, but there are not yet good human studies showing that BPC-157 works, how much to use, or what the long-term risks are. New human trials could change that picture.

Is BPC-157 safe? What the FDA has said

The FDA's page on compounding substances that may present significant safety risks says the agency lacks sufficient information to know whether BPC-157 would cause harm when given to humans. It also notes that compounded BPC-157 may pose a risk of immunogenicity (an unwanted immune reaction) for certain routes, and flags possible problems with peptide impurities. [6] That page's content is current as of April 22, 2026, which is before the HHS policy below. "We don't know enough" is not the same as "proven safe."

Quality is a second concern. BPC-157 sold online as "research use only" or "not for human consumption" is not made or checked for human use, and buying it that way skips any medical review. The HHS policy does not make those products legal for people. [1][2]

Where U.S. policy stands

The Federal Register notice (91 FR 68526, October 30, 2026) announces a draft "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances." It is an interim policy while the FDA's formal list of bulk substances that pharmacies may compound is developed through rulemaking. HHS says the policy is not binding and creates no rights, and that it may revisit it if a safety signal or product quality issue arises. Comments on the draft are open until about November 14, 2026. [1]

  • As of April 22, 2026, the FDA's bulk-substances page lists BPC-157 as nominated but withdrawn. A law-firm summary says it was previously in the FDA's "Category 2" of substances raising significant safety concerns. [6][2]
  • July 2026: the FDA's Pharmacy Compounding Advisory Committee voted to recommend several peptides, including BPC-157, for the list of substances pharmacies may compound, according to STAT. A committee vote is advice, not a final decision. [7]
  • October 23, 2026: according to one law-firm summary, a safety group filed a citizen petition asking the FDA not to allow compounding of these peptides. [2]
  • October 30, 2026: HHS published the draft interim policy, covering six peptides (BPC-157, TB-500, KPV, MOTS-c, Semax, and epitalon). [1][3]

What the draft HHS policy allows, and what it doesn't

The Federal Register notice says HHS does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician compounding a drug product using a listed peptide bulk drug substance. [1] According to legal summaries of the policy (we could not open the policy document itself, so confirm details against it), this applies only when conditions like these are met: [2][3]

  • It is compounded by a state-licensed 503A pharmacy or a licensed physician, for a specific patient, with a prescription.
  • Each product contains one peptide only. No blends or "stacks."
  • It is in an allowed form: for BPC-157, injectable (under the skin or into muscle), oral, or topical.
  • The raw ingredient comes from an FDA-registered facility with a valid certificate of analysis.
  • Serious side effects and quality problems are reported to the FDA and the state.
  • The label says it is a compounded drug product and not for resale.

According to those summaries, it does not cover 503B outsourcing facilities, so clinics can't keep BPC-157 on hand as office stock. It does not make BPC-157 FDA-approved. It does not legalize "research peptides" sold online. And because it is a draft and non-binding, HHS can change or withdraw it, especially if safety problems emerge. [1][3] State pharmacy boards may also have their own rules.

Is BPC-157 banned in sports?

BPC-157 is described as banned in professional sports. [4] Athletes subject to drug testing should check the current World Anti-Doping Agency Prohibited List before using any peptide, whatever the HHS policy says.

Red flags when shopping for BPC-157

  • "Research use only" or "not for human consumption" labels.
  • No medical evaluation or prescription required.
  • Blends or "healing stacks" that combine BPC-157 with other peptides in one vial (not allowed under the policy, according to legal summaries).
  • Claims that it is "FDA-approved," "clinically proven," or guaranteed to heal an injury.
  • No information about which pharmacy made it.

What you can do today

If you're interested in BPC-157 because you want to recover better, have more energy, or age well, talk with a licensed provider about your goals first. Many of the symptoms people hope peptides will fix, like fatigue, slow recovery, or poor sleep, have causes worth checking, from hormones to nutrition.

Compounded medications are not FDA-approved. The FDA does not verify the safety, effectiveness, or quality of compounded drugs before they are marketed. Compounded medications are prepared for individual patients based on a licensed provider's prescription.

Frequently asked questions

Is BPC-157 legal in the US right now?

BPC-157 is not FDA-approved. Under a draft HHS policy published October 30, 2026, HHS does not intend to take enforcement action against licensed 503A pharmacies and physicians that compound it for an individual patient with a prescription, if strict conditions are met. The policy is non-binding and could change. [1][3]

Is BPC-157 FDA-approved?

No. We found no FDA approval of BPC-157 for any use. The 2026 HHS policy is enforcement discretion, not approval. [1][6]

What is BPC-157 used for?

People use BPC-157 mainly hoping to speed recovery of tendons, ligaments, muscles, and the gut. Those uses are based mostly on animal studies. The most recent systematic review we found, which searched through June 1, 2026, identified three small human studies of very low certainty. [4][5]

What are the side effects of BPC-157?

The small human studies reported no treatment-related side effects, but they included only 30 people in total. The FDA says it lacks sufficient information to know whether BPC-157 would cause harm in humans, and that it may carry a risk of immune reactions for some routes. Long-term risks are unknown. [5][6]

Can I buy BPC-157 online?

Products sold online as "research use only" are not made for human use and are not covered by the HHS policy. Under the policy, BPC-157 must be compounded by a licensed pharmacy for a specific patient with a prescription. [1][2]

Sources

  1. Federal Register. Notice of availability: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, 91 FR 68526 (October 30, 2026).
  2. DPS Law. Is BPC-157 Legal? FDA and HHS Status, 2026 (updated Nov 2, 2026). Legal summary.
  3. BakerHostetler. HHS Issues Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (2026). Legal summary.
  4. Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025.
  5. Poolton JT, et al. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthop Belg. 2026.
  6. U.S. FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of Apr 22, 2026).
  7. STAT. FDA panel okays peptides for compounding pharmacies, including BPC-157 and KPV (Jul 23, 2026).